Lupus & antiphospholipid syndrome
Development and validation of quality indicators for lupus nephritis, based on the 2025 EULAR recommendations: adherence trends and impact on clinical outcomes
Authors' conclusion
Higher adherence was associated with reduced damage accrual in a tertiary centre cohort
Study context
- Population
- Contemporary lupus nephritis (LN) cohort, single tertiary centre; 23 experts rated candidate quality indicators (QIs)23 experts
- Participants
- 130 participants
- Comparison
- High vs lower per-patient adherence to QIs
- Outcome
- Core set of QIs based on the 2025 EULAR recommendations for LN, and their association with disease outcomes
Methodological detailsmodified RAND/UCLA appropriateness method, 2 voting rounds, single tertiary centre cohort
- Modified RAND/UCLA appropriateness method
- 2 voting rounds
- Single tertiary centre cohort
Performance
As reported in the abstract
QI set developed
QIs developed across 4 domains: diagnosis, treatment, monitoring, pregnancy
17
Adherence to combination immunosuppressive therapy as initial treatment (low)
10.7%
Further findings
| Outcome | OR (95% CI) | |
|---|---|---|
| Damage accrual (increase in SLICC/ACR DI) with high per-patient adherence | 0.29 (0.13–0.62) | |
| 0.10.31310Odds ratio (log scale) |
Renal flares with high per-patient adherence
- Fewer renal flares, not statistically significant
Original publication
Development and validation of quality indicators for lupus nephritis, based on the 2025 EULAR recommendations: adherence trends and impact on clinical outcomes. Ann Rheum Dis. Published 10 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →